Lexicon Pharmaceuticals (LXRX) Other Non-Current Assets (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Other Non-Current Assets of $368000.0 for Q1 2026, little changed year-over-year from $368000.0 in Q1 2025, and down 98.73% on a QoQ basis from $29.0 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 17 years of Other Non-Current Assets data on file, last reported at $368000.0 in Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $368000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $368000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $29.0 million, changed N/A from the prior year.
- Other Non-Current Assets eased to $368000.0 in Q1 2026 per LXRX's latest filing, from $29.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $29.0 million in Q3 2025 and bottomed at $368000.0 in Q1 2025.
- The 5-year median for Other Non-Current Assets is $828000.0 (2023), against an average of $5.5 million.
- The widest annual swing landed in 2023, when Other Non-Current Assets tumbled 89.6%; it then surged 3402.42% in 2025.
- Tracing LXRX's Other Non-Current Assets over 5 years: stood at $412000.0 in 2022, then surged by 100.97% to $828000.0 in 2023, then changed by 0.0% to $828000.0 in 2024, then surged by 3402.42% to $29.0 million in 2025, then sank by 98.73% to $368000.0 in 2026.
- Per Business Quant, the three latest LXRX Other Non-Current Assets figures stand at $368000.0 (Q1 2026), $29.0 million (Q4 2025), and $29.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | 368,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 368,000.00 |
| Dec 31, 2025 | 29.00 Mn |
| Sep 30, 2025 | 29.00 Mn |
| Jun 30, 2025 | 368,000.00 |
| Mar 31, 2025 | 368,000.00 |
| Sep 30, 2024 | 828,000.00 |
| Jun 30, 2024 | 828,000.00 |
| Mar 31, 2024 | 828,000.00 |
| Dec 31, 2023 | 828,000.00 |
| Sep 30, 2023 | 743,000.00 |
| Jun 30, 2023 | 6.26 Mn |
| Mar 31, 2023 | 6.42 Mn |
| Dec 31, 2022 | 412,000.00 |
| Sep 30, 2022 | 7.15 Mn |
| Jun 30, 2022 | 1.85 Mn |
| Mar 31, 2022 | 2.06 Mn |
| Dec 31, 2021 | 2.27 Mn |
| Sep 30, 2021 | 2.47 Mn |
| Jun 30, 2021 | 2.67 Mn |
| Mar 31, 2021 | 3.01 Mn |
| Dec 31, 2020 | 1.23 Mn |
| Sep 30, 2020 | 1.34 Mn |
| Jun 30, 2020 | 1.45 Mn |
| Mar 31, 2020 | 1.55 Mn |
| Dec 31, 2019 | 1.66 Mn |
| Sep 30, 2019 | 1.75 Mn |
| Jun 30, 2019 | 1.90 Mn |
| Mar 31, 2019 | 1.99 Mn |
| Dec 31, 2018 | 285,000.00 |
| Sep 30, 2018 | 429,000.00 |
| Jun 30, 2018 | 429,000.00 |
| Mar 31, 2018 | 432,000.00 |
| Dec 31, 2017 | 429,000.00 |
| Sep 30, 2017 | 429,000.00 |
| Jun 30, 2017 | 428,000.00 |
| Mar 31, 2017 | 428,000.00 |
| Dec 31, 2016 | 461,000.00 |
| Sep 30, 2016 | 454,000.00 |
| Jun 30, 2016 | 430,000.00 |
| Mar 31, 2016 | 530,000.00 |
| Dec 31, 2015 | 433,000.00 |
| Sep 30, 2015 | 3.50 Mn |
| Jun 30, 2015 | 3.58 Mn |
| Mar 31, 2015 | 3.74 Mn |
| Dec 31, 2014 | 3.41 Mn |
| Sep 30, 2014 | 23.85 Mn |
| Jun 30, 2014 | 120,000.00 |
| Mar 31, 2014 | 133,000.00 |
| Dec 31, 2013 | 144,000.00 |
| Sep 30, 2013 | 158,000.00 |
| Jun 30, 2013 | 65,000.00 |
| Mar 31, 2013 | 88,000.00 |
| Dec 31, 2012 | 109,000.00 |
| Sep 30, 2012 | 135,000.00 |
| Jun 30, 2012 | 157,000.00 |
| Mar 31, 2012 | 181,000.00 |
| Dec 31, 2011 | 205,000.00 |
| Sep 30, 2011 | 281,000.00 |
| Jun 30, 2011 | 253,000.00 |
| Dec 31, 2010 | 619,000.00 |